Celldex Therapeutics Inc (CLDX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $2.25B
Last updated: Nov 17, 2026 at 4:15 PM ET
Celldex Therapeutics Inc (CLDX) Statistics
Celldex Therapeutics (CLDX) has a market cap of $2.25B and an enterprise value of $2.22B. It kept -196854.78% of revenue as net income over the last 12 months. Revenue fell 93.96% over the last 12 months from the 12 months before.
Total Valuation
Enterprise value is 1.20% below the market cap, as cash exceeds debt.
| Market Cap | $2.25B |
|---|---|
| Enterprise Value | $2.22B |
| Latest price (Nov 17, 2026) | $28.04 |
Key Dates
The next earnings report is expected on Feb 23, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 23, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 5, 2026 |
| Fiscal Year End | December |
Valuation Ratios
| P/B Ratio | 3.4x |
|---|---|
| P/TBV Ratio | 3.5x |
Price Statistics
The stock is up 9.75% over 52 weeks and trades 11.10% below its 50-day average.
| Beta (1Y) | 1.22 |
|---|---|
| 52-Week Change | +9.75% |
| 1-Month Change | -5.49% |
| 3-Month Change | -32.76% |
| 6-Month Change | -7.00% |
| 5-Year Change | -29.24% |
| 10-Year Change | -36.26% |
| Total Return (1Y) | +9.75% |
| Total Return (3Y CAGR) | -1.22% |
| Total Return (5Y CAGR) | -7.99% |
| Return vs SPY (1Y) | -1.94% |
| Max Drawdown (1Y) | -38.65% |
| Max Drawdown (3Y) | -70.84% |
| Sharpe Ratio (1Y) | 0.18 |
| Correlation with SPY (1Y) | 0.33 |
| 50-Day Average | $31.54 |
| 200-Day Average | $32.88 |
| 52-Week Range | $22.33 to $45.14 |
| RSI (14 Days) | 40.3 |
| Average Volume (20 Days) | 872.67K |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 10.97x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 10.97x |
|---|---|
| Quick Ratio | 10.97x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is -47.59% over the last 12 months, against a 5-year average of -30.88%.
| Return on Equity (ROE) | -47.59% |
|---|---|
| Return on Assets (ROA) | -42.83% |
| ROE (5Y Average) | -30.88% |
| ROA (5Y Average) | -28.48% |
| ROIC (5Y Average) | -43.06% |
| Asset Turnover | 0.00x |
| Receivables Turnover | 0.54x |
Scores
CLDX has an Altman Z-Score of 13.85, in the safe zone above 2.99, and a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 13.85 |
|---|---|
| Altman Z Zone | Safe |
| Piotroski F-Score | 1 of 9 |
| Piotroski Strength | Weak |
Income Statement
Revenue was $157.00K over the last 12 months.
| Revenue | $157.00K |
|---|---|
| Revenue Growth (YoY) | -93.96% |
| Gross Profit | $157.00K |
| Operating Income | -$334.46M |
| Pretax Income | -$309.06M |
| Net Income | -$309.06M |
| Reported EPS (TTM) | -$4.30 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 90.01% of the $721.53M in total assets.
| Cash and Equivalents | $26.95M |
|---|---|
| Total Debt | $0 |
| Net Cash | $26.95M |
| Net Cash Per Share | $0.34 |
| Working Capital | $603.22M |
| Shareholder Equity | $649.47M |
| Book Value Per Share | $8.27 |
| Tangible Book Value | $622.28M |
| Tangible Book Per Share | $7.92 |
| Total Assets | $721.53M |
| Total Liabilities | $72.06M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $7.77M of capital spending, operating cash flow left -$259.74M of free cash flow.
| Operating Cash Flow | -$251.97M |
|---|---|
| Capital Expenditures | $7.77M |
| Free Cash Flow | -$259.74M |
| FCF Per Share | -$3.31 |
| Depreciation and Amortization | $7.73M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -213033.76%.
| Gross Margin | 100.00% |
|---|---|
| Operating Margin | -213033.76% |
| Pretax Margin | -196854.78% |
| Net Margin | -196854.78% |
| FCF Margin | -165438.85% |
Growth
Revenue fell 13.13% a year over 3 years.
| Revenue Growth (3Y CAGR) | -13.13% |
|---|---|
| Revenue Growth (5Y CAGR) | -26.93% |
| Book Value Per Share Growth (2Y CAGR) | -1.97% |
| Tangible Book Per Share Growth (2Y CAGR) | -1.35% |
Dividends and Yields
CLDX does not pay a dividend. Its free cash flow yield is -11.80%.
| FCF Yield | -11.80% |
|---|---|
| Buyback Yield | -14.87% |
| Shareholder Yield | -14.87% |
Stock Splits
The last split was a 1-for-15 reverse split on Feb 11, 2019.
| Last Split Date | Feb 11, 2019 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:15 |
Analyst Forecast
Consensus estimates put revenue growth at 114.50% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +114.50% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About CLDX
What is CLDX's market cap?
Celldex Therapeutics has a market cap of $2.25B. Its enterprise value, which adds debt and subtracts cash, is $2.22B.
How many shares of CLDX are outstanding?
Celldex Therapeutics has 78.53M shares outstanding. The count is up 18.23% from a year earlier.
Does CLDX pay a dividend?
No. Celldex Therapeutics does not pay a dividend.
How much debt does CLDX have?
Celldex Therapeutics has $0 of total debt and $26.95M of cash and equivalents, a net cash position of $26.95M.
CLDX pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors